Crenezumab

This drug entry is a **stub** and has not been fully annotated. It is scheduled to be annotated soon.

IDENTIFICATION

Name	Crenezumab
Accession Number	DB11959
Type	Biotech
Groups	Investigational
Biologic Classification	Protein Based Therapies Monoclonal antibody (mAb)
Description	Crenezumab has been used in trials studying the treatment of Alzheimer's Disease.
Protein chemical formula	Not Available
Protein average weight	Not Available
Sequences	Not Available
Synonyms	Not Available
External IDs	MABT5102A
Categories	Alzheimer Disease, drug therapy Amino Acids, Peptides, and Proteins Antibodies Blood Proteins Globulins Immunoglobulins Immunoproteins Proteins Serum Globulins
UNII	O8AS5277H0
CAS number	1095207-05-8

PHARMACOLOGY

Indication	Not Available
Pharmacodynamics	Not Available
Mechanism of action	Not Available
Absorption	Not Available

Volume of distribution	Not Available
Protein binding	Not Available
Metabolism	Not Available
Route of elimination	Not Available
Half life	Not Available
Clearance	Not Available
Toxicity	Not Available
Affected organisms	Not Available
Pathways	Not Available

Pharmacogenomic Effects/ADRs	Not Available

INTERACTIONS

Drug Interactions

ALL DRUGS | APPROVED | VET APPROVED | NUTRACEUTICAL | ILLICIT | WITHDRAWN | INVESTIGATIONAL | EXPERIMENTAL

Show 10 entries Search

DRUG	INTERACTION
Abciximab	The risk or severity of adverse effects can be increased when Abciximab is combined with Crenezumab.
Abituzumab	The risk or severity of adverse effects can be increased when Crenezumab is combined with Abituzumab.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Crenezumab.
Adecatumumab	The risk or severity of adverse effects can be increased when Adecatumumab is combined with Crenezumab.
Aducanumab	The risk or severity of adverse effects can be increased when Crenezumab is combined with Aducanumab.
Afelimomab	The risk or severity of adverse effects can be increased when Afelimomab is combined with Crenezumab.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Crenezumab.
Alirocumab	The risk or severity of adverse effects can be increased when Alirocumab is combined with Crenezumab.
Amatuximab	The risk or severity of adverse effects can be increased when Crenezumab is combined with Amatuximab.
AMG 108	The risk or severity of adverse effects can be increased when AMG 108 is combined with Crenezumab.

Showing 1 to 10 of 244 entries ‹ 1 2 3 4 5 ... 25 ›

Food Interactions	Not Available

REFERENCES

General References Not Available

Drugs

Wikipedia Crenezumab

CLINICAL TRIALS

Clinical Trials

Show 10 entries Search

PHASE	STATUS	PURPOSE	CONDITIONS	COUNT
1	Completed	Treatment	Healthy Volunteers	2
2	Active Not Recruiting	Treatment	Alzheimer's Disease (AD)	1
2	Completed	Treatment	Alzheimer's Disease (AD)	3
3	Active Not Recruiting	Treatment	Alzheimer's Disease (AD)	1
3	Recruiting	Treatment	Alzheimer's Disease (AD)	2

Showing 1 to 5 of 5 entries ‹ 1 ›

PHARMACOECONOMICS

Manufacturers	Not Available
Packagers	Not Available
Dosage forms	Not Available
Prices	Not Available
Patents	Not Available

PROPERTIES

State	Not Available
Experimental Properties	Not Available

TAXONOMY

Description	Not Available
Kingdom	Organic Compounds
Super Class	Organic Acids
Class	Carboxylic Acids and Derivatives
Sub Class	Amino Acids, Peptides, and Analogues
Direct Parent	Peptides
Alternative Parents	Not Available
Substituents	Not Available
Molecular	

Framework	Not Available

Drug created on October 20, 2016 15:05 / Updated on November 02, 2018 07:18

This project is supported by the **Canadian Institutes of Health Research** (award #111062), **Alberta Innovates - Health Solutions**, and by **The Metabolomics Innovation Centre (TMIC)**, a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by **Genome Alberta**, **Genome British Columbia**, and **Genome Canada**, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by **OMx Personal Health Analytics, Inc.** Designed by **Educe Design & Innovation Inc.**